Cover Image
市場調查報告書

Amura Holdings Ltd. - 產品平台檢討

Amura Holdings Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253747
出版日期 內容資訊 英文 22 Pages
訂單完成後即時交付
價格
Back to Top
Amura Holdings Ltd. - 產品平台檢討 Amura Holdings Ltd. - Product Pipeline Review - 2015
出版日期: 2015年04月29日 內容資訊: 英文 22 Pages
簡介

Amura Holdings Ltd.是總公司設置於英國的藥物研發企業,正在設計、開發變形關節炎,骨質疏鬆症,神經性疼痛,自體免疫狀態,轉移性骨骼疾病等治療藥。該公司也擁有治療細菌性感染疾病所採用的內醯胺抑制劑(AM-112)商標之專利權。

本報告提供Amura Holdings Ltd.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Amura Holdings Ltd.的基本資料

  • Amura Holdings Ltd.概要
  • 主要資訊
  • 企業資料

Amura Holdings Ltd.:R&D概要

  • 主要的治療範圍

Amura Holdings Ltd.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Amura Holdings Ltd.:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Amura Holdings Ltd.:藥物簡介

  • AM-112
  • AM-3701
  • AM-3840
  • AM-3876
  • Small Molecules to Inhibit Cathepsin for Malaria

Amura Holdings Ltd.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Amura Holdings Ltd.:開發暫停中的計劃

Amura Holdings Ltd.:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07021CDB

Summary

Global Markets Direct's, 'Amura Holdings Ltd. - Product Pipeline Review - 2015', provides an overview of the Amura Holdings Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Amura Holdings Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Amura Holdings Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Amura Holdings Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Amura Holdings Ltd.'s pipeline products

Reasons to buy

  • Evaluate Amura Holdings Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Amura Holdings Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Amura Holdings Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Amura Holdings Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Amura Holdings Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Amura Holdings Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Amura Holdings Ltd. Snapshot
    • Amura Holdings Ltd. Overview
    • Key Information
    • Key Facts
  • Amura Holdings Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Amura Holdings Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Amura Holdings Ltd. - Pipeline Products Glance
    • Amura Holdings Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Amura Holdings Ltd. - Drug Profiles
    • AM-112
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AM-3701
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AM-3840
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AM-3876
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Cathepsin for Malaria
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Amura Holdings Ltd. - Pipeline Analysis
  • Amura Holdings Ltd. - Pipeline Products by Target
  • Amura Holdings Ltd. - Pipeline Products by Route of Administration
  • Amura Holdings Ltd. - Pipeline Products by Molecule Type
  • Amura Holdings Ltd. - Pipeline Products by Mechanism of Action
  • Amura Holdings Ltd. - Dormant Projects
  • Amura Holdings Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Amura Holdings Ltd., Key Information
  • Amura Holdings Ltd., Key Facts
  • Amura Holdings Ltd. - Pipeline by Indication, 2015
  • Amura Holdings Ltd. - Pipeline by Stage of Development, 2015
  • Amura Holdings Ltd. - Monotherapy Products in Pipeline, 2015
  • Amura Holdings Ltd. - Preclinical, 2015
  • Amura Holdings Ltd. - Pipeline by Target, 2015
  • Amura Holdings Ltd. - Pipeline by Route of Administration, 2015
  • Amura Holdings Ltd. - Pipeline by Molecule Type, 2015
  • Amura Holdings Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Amura Holdings Ltd. - Dormant Developmental Projects,2015
  • Amura Holdings Ltd., Other Locations
  • Amura Holdings Ltd., Subsidiaries

List of Figures

  • Amura Holdings Ltd. - Pipeline by Top 10 Indication, 2015
  • Amura Holdings Ltd. - Pipeline by Top 10 Target, 2015
  • Amura Holdings Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Amura Holdings Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top